TY - JOUR
T1 - Intranasal Delivery of Functionalized Polymeric Nanomaterials to the Brain
AU - Zha, Shuai
AU - Wong, Ka Leung
AU - All, Angelo H.
N1 - Funding Information:
The authors would like to thank the following students—Alison Bartkowski, Ali Al Abdullatif, Kali Barnes, Stuart Bauer, Olivia Choi, Kiersten Colotti, Yinuo Zeng, Andrew Masteller, Ethan Cottrill, and Shengnan Zhang—for their limited contribution in this article. This study has been partially supported by the following grants at the Hong Kong Baptist University: Start‐Up Tier 1 Fund # 21.4531.162640 (PI: A.H.A.), Faculty Seed Fund # 31.4531.179234 (PI: A.H.A.), and Initiation Grant Faculty Niche Research Areas Fund RC‐FNRA‐IG/20‐21/SCI/02 (PI: A.H.A.).
Publisher Copyright:
© 2022 Wiley-VCH GmbH
PY - 2022/6/8
Y1 - 2022/6/8
N2 - Intravenous delivery of nanomaterials containing therapeutic agents and various cargos for treating neurological disorders is often constrained by low delivery efficacy due to difficulties in passing the blood-brain barrier (BBB). Nanoparticles (NPs) administered intranasally can move along olfactory and trigeminal nerves so that they do not need to pass through the BBB, allowing non-invasive, direct access to selective neural pathways within the brain. Hence, intranasal (IN) administration of NPs can effectively deliver drugs and genes into targeted regions of the brain, holding potential for efficacious disease treatment in the central nervous system (CNS). In this review, current methods for delivering conjugated NPs to the brain are primarily discussed. Distinctive potential mechanisms of therapeutic nanocomposites delivered via IN pathways to the brain are then discussed. Recent progress in developing functional NPs for applications in multimodal bioimaging, drug delivery, diagnostics, and therapeutics is also reviewed. This review is then concluded by discussing existing challenges, new directions, and future perspectives in IN delivery of nanomaterials.
AB - Intravenous delivery of nanomaterials containing therapeutic agents and various cargos for treating neurological disorders is often constrained by low delivery efficacy due to difficulties in passing the blood-brain barrier (BBB). Nanoparticles (NPs) administered intranasally can move along olfactory and trigeminal nerves so that they do not need to pass through the BBB, allowing non-invasive, direct access to selective neural pathways within the brain. Hence, intranasal (IN) administration of NPs can effectively deliver drugs and genes into targeted regions of the brain, holding potential for efficacious disease treatment in the central nervous system (CNS). In this review, current methods for delivering conjugated NPs to the brain are primarily discussed. Distinctive potential mechanisms of therapeutic nanocomposites delivered via IN pathways to the brain are then discussed. Recent progress in developing functional NPs for applications in multimodal bioimaging, drug delivery, diagnostics, and therapeutics is also reviewed. This review is then concluded by discussing existing challenges, new directions, and future perspectives in IN delivery of nanomaterials.
KW - brain delivery
KW - functionalized nanomaterials
KW - intranasal delivery
KW - nanomedicines
KW - polymeric nanomaterials
KW - therapeutic nanocarriers
UR - http://www.scopus.com/inward/record.url?scp=85125047655&partnerID=8YFLogxK
U2 - 10.1002/adhm.202102610
DO - 10.1002/adhm.202102610
M3 - Review article
C2 - 35166052
SN - 2192-2640
VL - 11
JO - Advanced healthcare materials
JF - Advanced healthcare materials
IS - 11
M1 - 2102610
ER -
